Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 28

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 in its annual financial statements only and does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements.In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statement disclosures.

Note 4.    Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):September 30,2025December 31,2024Savings and checking accounts at major U.S. financial institutions$709 $428 U.S. Treasury securities money market fund6,358 2,162 Total$7,067 $2,590 

7

Note 5.    Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):September 30,2025December 31,2024Prepaid insurance$732 $421 Prepaid research and development costs203 239 Prepaid other184 113 Total$1,119 $773 

Note 6.    Accrued Expenses

Accrued expenses consisted of the following (in thousands):September 30,2025December 31,2024Accrued research and development costs$481 $374 Accrued employee compensation-related expenses15 56 Accrued other65 78 Total$561 $508 

Note 7.    Stockholders’ Equity 

At The Market Offering AgreementOn July 3, 2024, the Company entered into